. HainesDR, GainesSP. N of 1 randomised controlled trials of ketamine in patients with chronic pain. Pain1999; 83: 283–7. DOI: 10.1016/S0304-3959(99)00117-7
2.
. EidePK, StubhaugA. Relief of glossopharyngeal neuralgia by ketamine-induced n-methyl-aspartate receptor blockade. Neurosurgery1997; 41: 505–8. DOI: 10.1097/00006123-199708000-00043
3.
. SotoE, StewartDR, MannesAJ, RuppertSL, Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 glomus tumor-associated complex regional pain syndrome. Am J Hosp Palliat Care2012; 29: 308–17. DOI: 10.1177/1049909111416345
4.
. McNultyJP, HahnK. Compounded oral ketamine for severe depression, anxiety, and pain in a hospital with end-stage chronic obstructive pulmonary disease, cardiopulmonary failure, and severe renal insufficiency: a case report. Int J Pharm Compound2012; 16: 364–8.
5.
. ReichDL, SilvayG. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth1989; 36: 186–97. DOI: 10.1007/BF03011442
6.
. Ketamine. In: DRUGDEX System. Greenwood Village, CO: Truven Healthcare. Updated periodically (accessed 2012 Dec 28).
7.
. Ketamine. In: TwycrossR, WilcockA, eds. 13: Anaesthesia. PCF4+: palliative care formulary. pdf version, September 2012. Palliativedrugs.com Ltd: Nottingham, England, 2012: 755–63.
. Code of Federal Regulations. Title 21 Food and Drugs, Chapter I, Food and Drug Administration, Department of Health and Human Services, Subchapter C—Drugs: General, Part 216 Pharmacy Compounding, Subpart B Compounded Drug Products. §216.24 Drug products withdrawn or removed from the market for reasons of safety or effectiveness.
10.
. Pharmaceutical compounding—nonsterile preparations. Stability criteria and beyond-use dating (Chapter 795). In: US Pharmacopoeia 35. Rockville MD: United States Pharmacopeial Convention, 2012: 348.
